Promotive Communications

Lab AugSept_2017digital latest

Laboratory Focus is Canada's leading editorial-based lab publication. Providing readers with the latest technology updates through application and tech notes, as well as covering new products and trends in laboratories across Canada.

Issue link:

Contents of this Issue


Page 2 of 19

3 Laboratory Focus August/September 2017 news Dynacare will inform how to im- prove the safety and effective- ness of the most commonly-used medications in children: antibiotics, analgesics and mental health medi- cation. The tests are non-invasive and are conducted using saliva. "Dynacare is proud to be a part of this initiative to make pharmacoge- nomic testing available to improve patient outcomes," says project co- lead, Dr. Yvan Côté, general man- ager of Dynacare Next. "We want continued from page 1 continued from page 1 laboratory-focus PUBLISHER/EDITOR-IN-CHIEF Terri Pavelic EDITOR Nestor Arellano CONTRIBUTING WRITERS Angela Stutz J. Tate Godfrey GRAPHIC DESIGNER Elena Pankova CONTROLLER John R. Jones MARKETING MANAGER Melisa Sukhdeo CIRCULATION DIRECTOR Mary Labao Tel: 905-841-7389 OFFICE: 226 Edward St. Unit 1 Aurora, ON L4G 3S8 Phone: 905-727-3875 Fax: 905-727-4428 E-mail: laboratory_focus@ SUBSCRIPTION INQUIRIES Fax: 905-727-4428 Laboratory Focus is published 4 times per year by Promotive Communications Inc. Legal Depository: National Library of Canada ISSN 40052410 Subscription rate in Canada $35/year; USA $60/year; other countries $100/year. All rights reserved. No part of this publication may be reproduced without written consent. Publications Mail Registration Number: 40052410 Return undeliverable Canadian addresses to circulation dept: 1-226 Edward Street, Aurora, ON L4G 3S8 E-mail: All opinions expressed herein are those of the contributors and do not necessarily reflect the views of the publisher or any person or organization associated with the magazine. If you would like to order hard copy or electronic reprints of articles, contact the GM salmon fillets were sold or for what purpose, and we're shocked to discover that they've entered the market at this time." Vigilance OGM Quebec, a Montreal- based, not-for-profit GMO monitoring group, tweeted: "4.5 tons of GE salm- on on the market without labelling, we are #1 guinea pigs in the world!" and later on Monday added, "Transgenic salmon is now sold in the country, without labelling." Media reports said that AquaBounty announced in August that it had sold approximately five tons of Salmon fil- lets in Canada after I received permis- sion from health authorities. AquAdvantage salmon are triploid. It has three sets of chromosomes whereas most animals have two sets. To create the salmon, a growth hormone regulating gene from a Pa- cific Chinook salmon, and a promoter from an ocean pout, was added to the Atlantic salmon's 40,000 genes. This enables the salmon to grow year- round instead of only during spring and summer. The ocean pout is an eel-like fish with antifreeze proteins in its blood to help it survive in near-freezing waters in eastern Canada and New England. The aim of the genetic modification is to increase the speed of growth of the salmon. The AquAdvantage Salmon fish grows to market size in 16 to 18 months rather than three years. The company went through three years of testing before the Health Ministry and the Canadian Food In- spection Agency ruled in May that AquaBounty's genetically modified salmon is "as safe and nutritious as conventional salmon." The salmon are raised in Panama. However, AquaBounty said it plans to produce the fish in Prince Edward Island. The company maintains that its genetically modified salmon are safe, nutritious and produced in a sustain- able manner. According to AquaBounty's Web site, the company's low impact fish farming method involves raising AquAdvantage salmon in land-based production sys- tems away from the ocean. "This eliminates the risk of escapes that could impact native fish popula- tions and the risk of pollutants or contaminants that could harm marine ecosystems," the company said. The AquAdvantage salmon are pro- duced sterile to safeguard the wild fish population. AquaBounty also claims its salmon grows to market size using 25 per cent less feed that traditional Atlantic salmon in the market. Agriculture Minister Lawrence MacAulay is holding several public consultations on the issue of GM foods across the country over the next two months. The meetings will include stake- holders, Indigenous representatives, experts, and key policy makers, Up for discussion will be food affordability, accessibility, safety and conservation. "Do I agree with GM? We have a regulatory system that's science- based. We promote it worldwide. I promote it worldwide," said MacAu- lay in an interview with the CBC. "If the science based regulatory system indicates food is safe for Canadians, I agree that they're safe for Canadians." However, groups like CBAN and Vigilance OGM are clamouring for transparency, better ways of alerting consumers of GM foods in the market place, and better federal government tracking of GM foods. "We clearly need mandatory labelling of all GM foods," said Thibault Rehn of the Quebec network Vigilance OGM. There is no federal government tracking of GM products in the market and members of parliament voted down a private members bill for man- datory GM food labelling in May, ac- cording to CBAN. GM salmon is approved for human consumption in the U.S. and Canada, but there is an import ban in the US until labelling guidelines are pub- lished, Sharratt pointed out. "When it comes to GM foods, Cana- dian consumers are shopping blind," she said. To see this story online visit ency-tracking-sought-in-sale-of-gm- salmon-in-canada/ to leverage technology in a way that can make medications safer and ulti- mately improve the delivery of care." The partnership also connects physicians and pharmacists across Canada in order to expand access to this innovative technology and ensure pharmacogenomic laboratory results are incorporated into medical decision-making. "Using pharmacogenomics to reduce the risk of adverse drug reactions and guide treatment deci- sions in children is an integral part of delivering precision health care," said Dr. Catalina Lopez-Correa, chief scientific officer and vice-president, Sectors, at Genome BC. "This work reflects Genome BC's ambition to translate genomics into everyday clinical applications, in particular at the primary care level, and improve health outcomes for all Canadians." To see this story online visit ics-project-looks-to-reduce-ad- verse-drug-reactions-in-children/ PM

Articles in this issue

Links on this page

view archives of Promotive Communications - Lab AugSept_2017digital latest